​

Alkermes (ALKS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ALKS Stock Forecast

Alkermes (ALKS) stock forecast, based on 9 Wall Street analysts, predicts a 12-month average price target of $37.50, with a high of $40.00 and a low of $36.00. This represents a 19.16% increase from the last price of $31.47.

$20 $24 $28 $32 $36 $40 High: $40 Avg: $37.5 Low: $36 Last Closed Price: $31.47

ALKS Stock Rating

Alkermes stock's rating consensus is Hold, based on 9 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (44.44%), 5 Hold (55.56%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Hold
Total 9 0 5 4 Strong Sell Sell Hold Buy Strong Buy

ALKS Price Target Upside V Benchmarks

TypeNameUpside
StockAlkermes19.16%
SectorHealthcare Stocks 25.00%
IndustryBiotech Stocks 63.52%

Price Target Trends

1M3M12M
# Anlaysts-29
Avg Price Target-$38.50$33.00
Last Closing Price$31.47$31.47$31.47
Upside/Downside-22.34%4.86%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 252741-14
Jan, 252751-15
Dec, 242741-14
Nov, 242771-17
Oct, 242671-16
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Dec 05, 2024David AmsellemPiper Sandler$37.00$31.2518.40%17.57%
Nov 13, 2024Vamil DivanMizuho Securities$40.00$26.0753.43%27.11%
Nov 04, 2024Paul MatteisStifel Nicolaus$36.00$26.5935.39%14.39%
Oct 24, 2024Paul MatteisStifel Nicolaus$25.00$26.85-6.89%-20.56%
Oct 14, 2024Douglas TsaoH.C. Wainwright$37.00$28.9127.98%17.57%
Apr 10, 2024Akash TewariJefferies$25.00$13.3786.99%-20.56%
Apr 09, 2024Vamil DivanMizuho Securities$35.00$26.7330.94%11.22%
Apr 09, 2024Akash TewariJefferies$25.00$26.95-7.24%-20.56%
Mar 18, 2024Joel BeattyRobert W. Baird$37.00$27.5334.40%17.57%
Dec 06, 2022J.P. Morgan$29.00$25.0115.95%-7.85%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 14, 2024H.C. WainwrightNeutralNeutralhold
Oct 14, 2024H.C. WainwrightBuyBuyhold
Oct 10, 2024Cantor FitzgeraldUnderperformUnderperformhold
Sep 23, 2024JefferiesBuyBuyhold
Jul 25, 2024H.C. WainwrightNeutralNeutralhold
Jul 15, 2024H.C. WainwrightBuyBuyhold
Jun 17, 2024Piper SandlerBuyBuyhold
Jun 17, 2024Cowen & Co.Buyinitialise
Jun 04, 2024JefferiesBuyBuyhold
May 23, 2024JefferiesUnderperformUnderperformhold

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.70$-0.30$-0.97$2.14-----
Avg Forecast$0.36$0.58$0.23$1.60$2.62$1.74$1.97$1.68$1.80
High Forecast$0.35$0.57$0.22$1.51$2.39$1.23$0.34$0.49$1.68
Low Forecast$0.37$0.61$0.24$1.79$2.80$1.98$2.76$2.60$1.88
Surprise %-294.44%-151.72%-521.74%33.75%-----

Revenue Forecast

$1B $1B $1B $1B $2B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.04B$1.17B$1.11B$1.66B-----
Avg Forecast$1.03B$1.16B$1.10B$1.65B$1.51B$1.41B$1.46B$1.43B$1.47B
High Forecast$1.00B$1.13B$1.05B$1.62B$1.48B$1.35B$1.45B$1.42B$1.39B
Low Forecast$1.06B$1.20B$1.13B$1.67B$1.52B$1.46B$1.47B$1.43B$1.52B
Surprise %1.15%1.35%1.37%0.85%-----

Net Income Forecast

$-1B $-600M $-200M $200M $600M $1B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-110.86M$-48.17M$-158.27M$355.76M-----
Avg Forecast$60.53M$-151.10M$-447.50M$519.16M$441.17M$272.37M$211.64M$210.29M$304.67M
High Forecast$58.60M$-190.54M$-539.19M$412.99M$406.34M$207.96M$57.12M$83.33M$285.39M
Low Forecast$63.35M$-111.66M$-355.81M$625.33M$476.00M$336.78M$469.15M$441.92M$319.43M
Surprise %-283.15%-68.12%-64.63%-31.47%-----

ALKS Forecast FAQ

Is Alkermes stock a buy?

Alkermes stock has a consensus rating of Hold, based on 9 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 5 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Alkermes is a neutral investment for most analysts.

What is Alkermes's price target?

Alkermes's price target, set by 9 Wall Street analysts, averages $37.5 over the next 12 months. The price target range spans from $36 at the low end to $40 at the high end, suggesting a potential 19.16% change from the previous closing price of $31.47.

How does Alkermes stock forecast compare to its benchmarks?

Alkermes's stock forecast shows a 19.16% upside, underperforming the average forecast for the healthcare stocks sector (25.00%) and underperforming the biotech stocks industry (63.52%).

What is the breakdown of analyst ratings for Alkermes over the past three months?

  • February 2025: 14.29% Strong Buy, 50.00% Buy, 28.57% Hold, 7.14% Sell, 0% Strong Sell.
  • January 2025: 13.33% Strong Buy, 46.67% Buy, 33.33% Hold, 6.67% Sell, 0% Strong Sell.
  • December 2024: 14.29% Strong Buy, 50.00% Buy, 28.57% Hold, 7.14% Sell, 0% Strong Sell.

What is Alkermes’s EPS forecast?

Alkermes's average annual EPS forecast for its fiscal year ending in December is $2.62 for 2024, a 22.43% increase from the reported $2.14 in 2023. The prediction for 2025 is $1.74, $1.97 for 2026, $1.68 for 2027, and $1.8 for 2028.

What is Alkermes’s revenue forecast?

Alkermes's average annual revenue forecast for its fiscal year ending in December is $1.51B for 2024, a -9.33% decrease from the reported $1.66B in 2023. The forecast for 2025 is $1.41B, $1.46B for 2026, $1.43B for 2027, and $1.47B for 2028.

What is Alkermes’s net income forecast?

For its fiscal year ending in December, Alkermes's average annual net income forecast is $441.17M for 2024, reflecting an 24.01% increase from the reported $355.76M in 2023. The projection for 2025 is $272.37M, $211.64M for 2026, $210.29M for 2027, and $304.67M for 2028.